{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:19:07Z","timestamp":1770913147033,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T00:00:00Z","timestamp":1370476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00417-013-2392-6","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T07:10:54Z","timestamp":1370416254000},"page":"2131-2139","source":"Crossref","is-referenced-by-count":26,"title":["Anti-angiogenic effect of KH902 on retinal neovascularization"],"prefix":"10.1007","volume":"251","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lvzhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,6]]},"reference":[{"key":"2392_CR1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D\u2019Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445\u2013450","journal-title":"Am J Ophthalmol"},{"key":"2392_CR2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"2392_CR3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archopht.1994.01090230090028","volume":"112","author":"F Malecaze","year":"1994","unstructured":"Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476\u20131482","journal-title":"Arch Ophthalmol"},{"key":"2392_CR4","first-page":"638","volume":"72","author":"J Pe\u2019er","year":"1995","unstructured":"Pe\u2019er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Inv; J Techmethods Path 72:638\u2013645","journal-title":"Lab Inv; J Techmethods Path"},{"key":"2392_CR5","first-page":"574","volume":"145","author":"JW Miller","year":"1994","unstructured":"Miller JW, Adamis AP, Shima DT, D\u2019Amore PA, Moulton RS, O\u2019Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, Yeo TK, Yeo KT (1994) Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574\u2013584","journal-title":"Am J Pathol"},{"key":"2392_CR6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","volume":"92","author":"EA Pierce","year":"1995","unstructured":"Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905\u2013909","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2392_CR7","doi-asserted-by":"crossref","unstructured":"Smith LE (2004) Pathogenesis of retinopathy of prematurity. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 14 Suppl A: S140-144","DOI":"10.1016\/j.ghir.2004.03.030"},{"key":"2392_CR8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ophtha.2003.10.030","volume":"111","author":"MF Chiang","year":"2004","unstructured":"Chiang MF, Arons RR, Flynn JT, Starren JB (2004) Incidence of retinopathy of prematurity from 1996 to 2000: analysis of a comprehensive New York state patient database. Ophthalmology 111:1317\u20131325","journal-title":"Ophthalmology"},{"key":"2392_CR9","doi-asserted-by":"crossref","unstructured":"(1996) Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1\/2 years after randomization. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Archives of ophthalmology 114: 417\u2013424","DOI":"10.1001\/archopht.1996.01100130413008"},{"key":"2392_CR10","doi-asserted-by":"crossref","unstructured":"(2001) Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Archives of ophthalmology 119: 1110\u20131118","DOI":"10.1001\/archopht.119.8.1110"},{"key":"2392_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1726-4901(10)70062-9","volume":"73","author":"LS Teng","year":"2010","unstructured":"Teng LS, Jin KT, He KF, Wang HH, Cao J, Yu DC (2010) Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc: JCMA 73:281\u2013288","journal-title":"J Chin Med Assoc: JCMA"},{"key":"2392_CR12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12094-011-0749-z","volume":"13","author":"K Jin","year":"2011","unstructured":"Jin K, He K, Teng F, Li G, Wang H, Han N, Xu Z, Cao J, Wu J, Yu D, Teng L (2011) FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. Clin Transl Oncol: Off Publ Fed Span Oncol Soc National Cancer Inst Mex 13:878\u2013884","journal-title":"Clin Transl Oncol: Off Publ Fed Span Oncol Soc National Cancer Inst Mex"},{"key":"2392_CR13","first-page":"37","volume":"14","author":"M Zhang","year":"2008","unstructured":"Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D (2008) Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 14:37\u201349","journal-title":"Mol Vis"},{"key":"2392_CR14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","volume":"26","author":"M Zhang","year":"2009","unstructured":"Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26:204\u2013210","journal-title":"Pharm Res"},{"key":"2392_CR15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","volume":"118","author":"M Zhang","year":"2011","unstructured":"Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu DC (2011) A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118:672\u2013678","journal-title":"Ophthalmology"},{"key":"2392_CR16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.112.192575","volume":"342","author":"YJ Bai","year":"2012","unstructured":"Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX (2012) Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342:131\u2013139","journal-title":"J Pharmacol Exp Ther"},{"key":"2392_CR17","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A, Kostyk SK, D\u2019Amato R, Sullivan R, D\u2019Amore PA (1994) Oxygen-induced retinopathy in the mouse. Investig Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2392_CR18","unstructured":"Zhou GHYW, Li XX (2007) Expression of Cathepsin B in the development of retinal neovascularization. Chin J of Exp Ophthalmol 25"},{"key":"2392_CR19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1167\/iovs.11-8788","volume":"53","author":"W Du","year":"2012","unstructured":"Du W, Yu W, Huang L, Zhao M, Li X (2012) Ephrin-a4 is involved in retinal neovascularization by regulating the VEGF signaling pathway. Investig Ophthalmol Vis Sci 53:1990\u20131998","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2392_CR20","first-page":"526","volume":"118","author":"J Chen","year":"2008","unstructured":"Chen J, Connor KM, Aderman CM, Smith LE (2008) Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 118:526\u2013533","journal-title":"J Clin Invest"},{"key":"2392_CR21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","volume":"114","author":"EA Pierce","year":"1996","unstructured":"Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219\u20131228","journal-title":"Arch Ophthalmol"},{"key":"2392_CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","volume":"10","author":"J Chen","year":"2007","unstructured":"Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133\u2013140","journal-title":"Angiogenesis"},{"key":"2392_CR23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/IAE.0b013e3181a3b848","volume":"29","author":"NI Nonobe","year":"2009","unstructured":"Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, Hayakawa M, Terasaki H (2009) Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 29:579\u2013585","journal-title":"Retina"},{"key":"2392_CR24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5301\/ejo.5000176","volume":"22","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA (2012) Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 22:685\u2013686","journal-title":"Eur J Ophthalmol"},{"key":"2392_CR25","first-page":"1149","volume":"6","author":"AM Carneiro","year":"2012","unstructured":"Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao-Reis FM (2012) Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol 6:1149\u20131157","journal-title":"Clin Ophthalmol"},{"key":"2392_CR26","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"TY Lai","year":"2012","unstructured":"Lai TY, Luk FO, Lee GK, Lam DS (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 26:1004\u20131011","journal-title":"Eye (Lond)"},{"key":"2392_CR27","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1074\/jbc.M411395200","volume":"280","author":"K Suto","year":"2005","unstructured":"Suto K, Yamazaki Y, Morita T, Mizuno H (2005) Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 280:2126\u20132131","journal-title":"J Biol Chem"},{"key":"2392_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5551\/jat.E496","volume":"15","author":"S Miura","year":"2008","unstructured":"Miura S, Matsuo Y, Saku K (2008) Jun N-terminal kinase inhibitor blocks angiogenesis by blocking VEGF secretion and an MMP pathway. J Atheroscler Thromb 15:69\u201374","journal-title":"J Atheroscler Thromb"},{"key":"2392_CR29","doi-asserted-by":"crossref","first-page":"50446","DOI":"10.1074\/jbc.M409221200","volume":"279","author":"J Yu","year":"2004","unstructured":"Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S (2004) p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 279:50446\u201350454","journal-title":"J Biol Chem"},{"key":"2392_CR30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1463-1326.2012.01584.x","volume":"14","author":"J Huang","year":"2012","unstructured":"Huang J, Li X, Li M, Li S, Xiao W, Chen X, Cai M, Wu Q, Luo D, Tang S, Luo Y (2012) Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab 14:644\u2013653","journal-title":"Diabetes Obes Metab"},{"key":"2392_CR31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/mt.2011.285","volume":"20","author":"DC Yu","year":"2012","unstructured":"Yu DC, Lee JS, Yoo JY, Shin H, Deng H, Wei Y, Yun CO (2012) Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther: J Am Soc Gene Ther 20:938\u2013947","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"2392_CR32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","volume":"97","author":"H Li","year":"2012","unstructured":"Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X (2012) Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 97:154\u2013159","journal-title":"Exp Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-013-2392-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-013-2392-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-013-2392-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T18:32:28Z","timestamp":1563129148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-013-2392-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,6]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1007\/s00417-013-2392-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,6]]}}}